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Ozge Kizilay Mancini1, Dominique Shum-Tim2, Ursula Stochaj3, José A. Correa4 and Inés Colmegna5,6*Erratum
The original article [1] contains a mistakenly short-
ened abstract due to a misinterpretation during its
production.
As such, the full abstract should read as follows:
Abstract
Atherosclerosis is an age-associated, multifactorial
process driven by immune activation and inflammation.
Ongoing clinical trials aim to establish the role of mes-
enchymal stromal cells (MSCs) as therapeutic agents in
atherosclerosis. The beneficial effects of MSCs derive
from their immune-modulatory properties. Under-
standing the impact of aging and age-associated condi-
tions (i.e., type 2 diabetes mellitus and atherosclerosis)
on MSC function is key to maximizing their therapeutic
potency. The aim of this study was to assess the effect
of chronological and biological aging on human MSC-
mediated CD4+ T-cell suppression. To this end human
MSCs were isolated from adipose tissue and the
MSC:CD4+ T-cell suppression was assessed in a co-
culture system. MSCs from elderly donors (≥65 years)
had significantly lower T-cell suppressive capacity
compared to those from donors <65 years (p = 0.003).
Furthermore, MSCs from patients with atherosclerosis
and type 2 diabetes mellitus were less efficient at sup-
pressing T-cell proliferation (atherosclerosis, p = 0.02;
type 2 diabetes mellitus, p = 0.04; compared to non-
disease controls). Sex and tobacco use did not impact
the immunosuppressive capacity of MSCs. In summary,
this study demonstrates that advanced age, atheroscler-
osis and type 2 diabetes mellitus reduce the functional* Correspondence: ines.colmegna@mcgill.ca
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tion of MSC donors could enhance the results of cell-
based therapies.
Author details
1Department of Anatomy and Cell Biology, McGill University, Montreal, QC,
Canada. 2Division of Cardiothoracic Surgery and Surgical Research, Royal
Victoria Hospital, McGill University Health Center, Montreal, QC, Canada.
3Department of Physiology, McGill University, Montreal, QC, Canada.
4Department of Mathematics and Statistics, McGill University, Montreal, QC,
Canada. 5Division of Rheumatology, Department of Medicine, McGill
University, Montreal, QC, Canada. 6Royal Victoria Hospital, McGill University
Health Centre, 1001 Boulevard, Décarie, Montréal, Québec H4A 3J1, Canada.
Received: 8 February 2017 Revised: 8 February 2017
Accepted: 8 February 2017
Reference
1. Kizilay M, et al. Age, atherosclerosis and type 2 diabetes reduce human
mesenchymal stromal cell-mediated T-cell suppression. Stem Cell Res Ther.
2015;6:140.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
